Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL)On track to report a clinical update for ADI-001 in second half of 2024Plan to file Investigational New Drug Application (IND) for ADI-925 in H2...
/PRNewswire/ -- The "Allogeneic Cell Therapy: Global Market Report 2023-2035" report has been added to ResearchAndMarkets.com's offering. The global allogeneic...
Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma On track to report a...
Adicet Bio (NASDAQ:ACET – Get Free Report) is scheduled to announce its earnings results on Tuesday, August 8th. Adicet Bio (NASDAQ:ACET – Get Free Report) last announced its quarterly earnings data on Tuesday, May 9th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.02. On […]
Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 2,960,000 shares, a decrease of 5.7% from the June 30th total of 3,140,000 shares. Based on an average trading volume of 835,400 shares, […]